Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies
Contact us

About Us

At a glance

Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia.

Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.

Our lead product Feraccru®/Accrufer® is a novel, stable, non-salt based oral therapy and is approved in the United States, European Union, UK and Switzerland for the treatment of iron deficiency with or without anaemia in adults.

In Europe the product is marketed as Feraccru® with commercialisation led by Norgine BV. In the USA the product will be marketed as Accrufer®. We are currently in the process of selecting a partner for the US market.

We also have an exclusive licence agreement with ASK Pharm who will lead development and commercialisation in China, Hong Kong, Macau and Taiwan.

We have an active product pipeline and partnering opportunities.

How we do business

 

What sets us apart

  • Lead product Feraccru® / Accrufer®

    Our lead product is approved for the treatment of iron deficiency with or without anaemia in adults in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid 2030s.

    In Europe the product is marketed as Feraccru® with commercialisation led by Norgine BV. In the USA – where the product benefits from NCE exclusivity until 2024 – it will be marketed as Accrufer®.

    In China we are working closely with ASK Pharm who will lead development and commercialisation in this region.

  • Large market opportunities with unmet needs

    The US is the world’s largest and most attractively reimbursed pharmaceutical market. There are between 8 million and 9 million patients in the USA who suffer from iron deficiency anaemia and potentially two to three times this number require treatment for iron deficiency. Our lead product is approved by the FDA and will be marketed in the US as Accrufer®.

    In Europe our lead product is marketed as Feraccru® and is available to treat the estimated 40 million people with iron deficiency, representing another significant commercial opportunity.

  • Experienced management team with extensive expertise

    The skilled senior management team and board of directors provide strong leadership for the Company’s future growth.

  • Strong intellectual property protection

    The Group’s assets are supported by a suite of robust intellectual property rights including key patents in major markets. Feraccru® / Accrufer®, for the treatment of Iron Deficiency with or without anaemia in adults benefits from data exclusivity protection in Europe and the USA and has exclusive IP rights until the mid-2030’s.

Reasons to invest in Shield.

Large markets of patients poorly treated for iron deficiency

Large markets of patients poorly treated for iron deficiency

2 billion
WHO estimates of global prevalence of Iron Deficiency

Feraccru© approved and launched in Europe

Feraccru© approved and launched in Europe

Partnered with Norgine in Europe, Australia and New Zealand
40 million ID sufferers in Europe

Licensed to ASK Pharm in China

Licensed to ASK Pharm in China

Population of 1.4 billion people

Accrufer© approved in USA

Accrufer© approved in USA

Partnering process underway
10 million IDA patients in USA

Feracru©/Accrufer© patants extend to

Feracru©/Accrufer© patants extend to

2035

Novel phosphate binder in pipeline

Novel phosphate binder in pipeline

Current cash runway extends to

Current cash runway extends to

Q1-2021

Download our Investment Case

Meet the team

Our people are committed, effective and determined to succeed. Everyone is valued.

Chief Executive Officer

Tim Watts

Read More

Chief Executive Officer

Tim Watts

Tim has worked in the pharmaceuticals and biotech sectors since 1990 when he joined ICI Pharmaceuticals which evolved into AstraZeneca. In his 17 years with AstraZeneca he worked primarily in Finance roles supporting commercial operations, in particular as VP Finance in the International Sales and Marketing Organisation, but also spent two years in a commercial role. His last position in AstraZeneca was as Group Financial Controller. In 2007 Tim became CFO of Archimedes Pharma, a UK-based private equity backed specialty pharma company where he was Interim COO for a period, and then in 2012 joined Oxford BioMedica PLC, a UK-listed gene and cell therapy company, as CFO. Tim joined Shield as CFO in August 2018 and was appointed CEO in April 2020.

General Counsel and Company Secretary

Lucy Bailey

Read More

General Counsel and Company Secretary

Lucy Bailey

Lucy Bailey has been the Group’s Legal Advisor since August 2015 and was an integral member of the team working towards the successful admission of Shield Therapeutics to the AIM market in early 2016. Having worked previously at a boutique corporate law firm and prior to that an international US law firm in Singapore, Lucy brings to Shield a wealth of experience in the oil and gas sector as well as the pharmaceutical industry. Lucy was promoted to Senior In-House Counsel in December 2016, General Counsel in 2018 and is responsible for the management of the Group’s legal team and all legal advice and services. Lucy was appointed by the Board of Directors to the role of Company Secretary in September 2017. Lucy is admitted as a Solicitor of the Senior Courts of England and Wales.

VP Commercial Operations

David Childs

Read More

VP Commercial Operations

David Childs

David joined Shield Therapeutics in 2011 as Director of Manufacturing with the primary objective of creating a robust manufacturing process with multiple CMOs for the development and commercialisation of our lead product, Feraccru®. During his tenure David has also had a central role in developing and managing the Company’s intellectual property, whilst more recently adding responsibility for the development of commercial alliances. Prior to joining Shield, David gained over 18 years’ of experience in chemical and pharmaceutical development at GlaxoSmithKline (GSK), where he led several successful projects and teams including the manufacturing elements of the successful Promacta® and Relovair® developments.

VP Regulatory Affairs and Quality

Dr Jackie Mitchell

Read More

VP Regulatory Affairs and Quality

Dr Jackie Mitchell

Jackie has over 20 years’ experience in regulatory affairs. She holds an MA in biochemistry from Lady Margaret Hall in Oxford, where she also obtained a doctorate in immunology and molecular biology. Following completion of her academic studies, Jackie spent a number of years working as a research scientist, including a period at Johns Hopkins School of Medicine in Baltimore, USA. Since moving into the pharmaceutical industry, Jackie has worked in regulatory affairs for large, medium and small pharmaceutical companies, including Boehringer Ingelheim, Abbott and Archimedes. She has been involved in a broad range of global, EU and national applications across many therapeutic areas and has led several major regulatory projects, including successful MAA and NDA submissions, including the NCEs Kaletra and Humira. Jackie has run the group’s regulatory activities since 2012.

 

View all